Lista de obras - Anna Jonasova - Dominio Público Uruguay

5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.

artículo científico publicado en 2012

A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.

artículo científico publicado en 2013

Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment.

artículo científico publicado en 2015

Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice

artículo científico publicado en 2013

Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q).

artículo científico publicado en 2012

Characterization of chromosome 11 breakpoints and the areas of deletion and amplification in patients with newly diagnosed acute myeloid leukemia.

artículo científico publicado en 2013

Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.

artículo científico publicado en 2016

Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow

scientific article published on 01 February 1998

DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population

artículo científico publicado en 2013

Defective cytotoxicity of T lymphocytes in myelodysplastic syndrome

artículo científico publicado en 2009

Deletion of the long arm but not the 5q31 region of chromosome 5 in myeloid malignancies

artículo científico publicado en 2011

Differential expression of homologous recombination DNA repair genes in the early and advanced stages of myelodysplastic syndrome.

artículo científico publicado en 2017

Dynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes patients treated with 5-azacytidine.

artículo científico publicado en 2016

Effect of erythropoietin on hepcidin expression in hemojuvelin-mutant mice

artículo científico publicado en 2010

Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome

scientific article published on 01 January 2011

Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5.

artículo científico publicado en 2014

Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation.

artículo científico publicado en 2011

Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide

artículo científico publicado en 2014

High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

artículo científico publicado en 2014

Involvement of deleted chromosome 5 in complex chromosomal aberrations in newly diagnosed myelodysplastic syndromes (MDS) is correlated with extremely adverse prognosis

artículo científico publicado en 2014

Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome

artículo científico publicado en 2015

Molecular cytogenetic analysis of dicentric chromosomes in acute myeloid leukemia.

artículo científico publicado en 2016

NQO1*2 polymorphism predicts overall survival in MDS patients.

artículo científico publicado en 2018

Nature of frequent deletions in CEBPA.

artículo científico publicado en 2009

Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes

artículo científico publicado en 2014

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

artículo científico publicado en 2016

Recurrent chromosomal breakpoints in patients with myelodysplastic syndromes and complex karyotype versus fragile sites.

artículo científico publicado en 2012

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes

artículo científico publicado en 2016

The translocation t(2;11)(p21;q23) without MLL gene rearrangement--a possible marker of good prognosis in myelodysplastic syndrome patients.

artículo científico publicado en 2013

Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q− MDS (IPSS low and intermediate-1)

artículo científico publicado en 2012

Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond-Blackfan anemia.

artículo científico publicado en 2012

Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms

artículo científico publicado en 2016

Lista de obras de Anna Jonasova

5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.

A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.

Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment.

Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice

Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q).

Characterization of chromosome 11 breakpoints and the areas of deletion and amplification in patients with newly diagnosed acute myeloid leukemia.

Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.

Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow

DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population

Defective cytotoxicity of T lymphocytes in myelodysplastic syndrome

Deletion of the long arm but not the 5q31 region of chromosome 5 in myeloid malignancies

Differential expression of homologous recombination DNA repair genes in the early and advanced stages of myelodysplastic syndrome.

Dynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes patients treated with 5-azacytidine.

Effect of erythropoietin on hepcidin expression in hemojuvelin-mutant mice

Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome

Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5.

Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation.

Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide

High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

Involvement of deleted chromosome 5 in complex chromosomal aberrations in newly diagnosed myelodysplastic syndromes (MDS) is correlated with extremely adverse prognosis

Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome

Molecular cytogenetic analysis of dicentric chromosomes in acute myeloid leukemia.

NQO1*2 polymorphism predicts overall survival in MDS patients.

Nature of frequent deletions in CEBPA.

Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

Recurrent chromosomal breakpoints in patients with myelodysplastic syndromes and complex karyotype versus fragile sites.

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes

The translocation t(2;11)(p21;q23) without MLL gene rearrangement--a possible marker of good prognosis in myelodysplastic syndrome patients.

Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q− MDS (IPSS low and intermediate-1)

Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond-Blackfan anemia.

Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms